Detection of sivelestat and its metabolite in small volumes of plasma from Chinese ALI/ARDS patients with SIRS via high-throughput UPLC-MS/MS: A pharmacokinetic study
Mingzhou Liu,Jing Zhang,Lingfang Dong,Wenhua Xue,Qilin He,Wenzhong Liang,Xing Liu,Jingying Zhang,Li Gu,Yinghua Feng,Jie Yang,Haibo Wang,Yaqin Wang,Kun Li,Yuanlong Li,Weiqin Kong,Xiaojian Zhang,Mengying Yao,Kai Wang,Peizhi Ma,Wei Zhang
DOI: https://doi.org/10.1016/j.jpba.2020.113876
IF: 3.571
2021-02-01
Journal of Pharmaceutical and Biomedical Analysis
Abstract:<p>In this study, we developed a sensitive and efficient analytical approach combining a 96-well plate-based protein precipitation strategy with ultra-performance liquid chromatography electrospray ionization tandem mass spectrometry (UPLC-MS/MS) in order to assess the pharmacokinetic (PK) properties of sivelestat and its metabolite XW-IMP-A in samples of plasma from ALI/ARDS patients with SIRS. The samples were separated via gradient elution with a C18 column (Phenomenex Kinetex, C18, 2.6 μm, 100 Å, 50 × 2.1 mm) using 0.1% formic acid aqueous solution (A) and acetonitrile-methanol (1:1, V:V) (B) as a mobile phase at a 0.6 mL/min flow rate. UPLC-MS/MS spectra were generated in positive ion mode, and multiple reaction monitoring (MRM) was used to detect the following transitions: <em>m/z</em> 435.1 → 360.0 for sivelestat, <em>m/z</em> 469.0 → 394.0 for sivelestat-IS, <em>m/z</em> 351.0 → 276.0 for XW-IMP-A, and <em>m/z</em> 384.9 → 310.0 for XW-IMP-A-IS. This assay was run for 2.5 minutes in total, and achieved lowest limit of quantitation values of 2.0 ng/mL and 0.5 ng/mL for sivelestat and XW-IMP-A, respectively, while remaining highly linear from 2-500 ng/mL for sivelestat ( <em>r<sup>2</sup></em> ≥ 0.9900) and from 0.5-125 ng/mL for XW-IMP-A ( <em>r<sup>2</sup></em> ≥ 0.9900). These validated data were consistent with US Food and Drug Administration (FDA) and European Medicines Agency (EMA) acceptance criteria. In addition, this method was successfully applied to the steady-state PK evaluation of ALI/ARDS patients with SIRS.</p>
pharmacology & pharmacy,chemistry, analytical